Africa and Middle East Cardiovascular Epidemiological Study

NCT01243138 | Completed

• 1 other identifier: A2581186
• Study Type: observational
• Target: 4,386
• Locations: 14 countries
• Sites: 73

Brief Summary

This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated.

Conditions

Obesity; Smoking; Dyslipidemia; Diabetes Mellitus; Hypertension

Keywords

Cross-sectional; epidemiological study; to evaluate the prevalence of CV risk factors in patients attending general practice in AfME region

Outcome Measures

Primary Outcomes (1)

• Prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension

  At the time of the first visit

Secondary Outcomes (5)

• Compare the prevalence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the urban and rural population.

  At the time of the first visit

• Compare the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension in the male and female population.

  At the time of the first visit

• Stratifying the prevalence of CV risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension by age groups.

  At the time of the first visit

• Ascertain the level of blood pressure and lipids' control as per the European Society of Cardiology (ESC) guidelines in patients who have been previously diagnosed as hypertensive or dyslipidaemic.

  At the time of the first visit

• Ascertain the most commonly used medications in those that have been previously diagnosed as diabetic, hypertensive or dyslipidaemic.

  At the time of the first visit

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Subject selection would be from clinics in a primary care setting

You may qualify if:

• Adult aged 18 or above

You may not qualify if:

• Pregnant women and/or lactating mothers
• Subjects presenting with any life threatening disease/condition

Sponsors & Collaborators

• Pfizer's Upjohn has merged with Mylan to form Viatris Inc.: lead

Study Sites (73)

Pfizer Investigational Site

Algiers, 16015, Algeria

Location

Pfizer Investigational Site

Bejaja, 6000, Algeria

Location

Pfizer Investigational Site

Djelfa, 17000, Algeria

Location

Pfizer Investigational Site

Laghouat, Algeria

Location

Pfizer Investigational Site

M'Sila, Algeria

Location

Pfizer Investigational Site

Relizane, 48000, Algeria

Location

Pfizer Investigational Site

Saïda, 20000, Algeria

Location

Pfizer Investigational Site

Tébessa, Algeria

Location

Pfizer Investigational Site

Tlemcen, 13000, Algeria

Location

Pfizer Investigational Site

Yaoundé, Cite Verte, Cameroon

Location

Pfizer Investigational Site

Douala, Deido, Cameroon

Location

Pfizer Investigational Site

Bafoussam, Cameroon

Location

Pfizer Investigational Site

Mbandjok, Cameroon

Location

Pfizer Investigational Site

Njombé, Cameroon

Location

Pfizer Investigational Site

Okoa, Cameroon

Location

Pfizer Investigational Site

Alexandria, Egypt

Location

Pfizer Investigational Site

Cairo, Egypt

Location

Pfizer Investigational Site

Shiben Al Kom, Egypt

Location

Pfizer Investigational Site

Tanta, Egypt

Location

Pfizer Investigational Site

Accra, Ghana

Location

Pfizer Investigational Site

Jachie-Ashanti, Ghana

Location

Pfizer Investigational Site

Kumasi, Ghana

Location

Pfizer Investigational Site

Sogakope V/R, Ghana

Location

Pfizer Investigational Site

Takoradze, Ghana

Location

Pfizer Investigational Site

Amman, Jordan

Location

Pfizer Investigational Site

Irbid, Jordan

Location

Pfizer Investigational Site

Salt, Jordan

Location

Pfizer Investigational Site

Chongoria, 60401, Kenya

Location

Pfizer Investigational Site

Nairobi, 00508, Kenya

Location

Pfizer Investigational Site

Adailiya, Kuwait

Location

Pfizer Investigational Site

Al Faḩāḩīl, Kuwait

Location

Pfizer Investigational Site

Kuwait City, Kuwait

Location

Pfizer Investigational Site

Mishrif, Kuwait

Location

Pfizer Investigational Site

Qadesya, Kuwait

Location

Pfizer Investigational Site

Yarmouk, Kuwait

Location

Pfizer Investigational Site

Jbeil, Lebanon, Lebanon, Lebanon

Location

Pfizer Investigational Site

Beirut, Lebanon

Location

Pfizer Investigational Site

Jounieh, Lebanon

Location

Pfizer Investigational Site

Tripoli, Lebanon

Location

Pfizer Investigational Site

Abuja, FCT, Nigeria

Location

Pfizer Investigational Site

Abuja, Garki, Nigeria

Location

Pfizer Investigational Site

Calabar, Nigeria

Location

Pfizer Investigational Site

Enugu, Nigeria

Location

Pfizer Investigational Site

Keffi, Nassarawa, Nigeria

Location

Pfizer Investigational Site

Dammam, Saudi Arabia

Location

Pfizer Investigational Site

Jeddah, Saudi Arabia

Location

Pfizer Investigational Site

Mecca, Saudi Arabia

Location

Pfizer Investigational Site

Riyadh, 11584, Saudi Arabia

Location

Pfizer Investigational Site

Riyadh, Saudi Arabia

Location

Pfizer Investigational Site

Yanbu, Saudi Arabia

Location

Pfizer Investigational Site

Dakar, Nabil Choucair, Senegal

Location

Pfizer Investigational Site

Dakar, Ouakam, Senegal

Location

Pfizer Investigational Site

Kedoungou, Senegal

Location

Pfizer Investigational Site

Kébémer, Senegal

Location

Pfizer Investigational Site

Saint-Louis, Senegal

Location

Pfizer Investigational Site

Ziguinchor, Senegal

Location

Pfizer Investigational Site

Halfway House, Gauteng, 1685, South Africa

Location

Pfizer Investigational Site

Sydenham, Durban, KwaZulu-Natal, 4091, South Africa

Location

Pfizer Investigational Site

Mokopane, Limpopo, 0600, South Africa

Location

Pfizer Investigational Site

Sheshego, Limpopo, 0742, South Africa

Location

Pfizer Investigational Site

Mamelodi East, Pretoria, 0122, South Africa

Location

Pfizer Investigational Site

Kwa-Zulu Natal, 4091, South Africa

Location

Pfizer Investigational Site

Rondebosch, 7700, South Africa

Location

Pfizer Investigational Site

Aryanah, 2073, Tunisia

Location

Pfizer Investigational Site

Bouficha, 4010, Tunisia

Location

Pfizer Investigational Site

Messaadine, 4013, Tunisia

Location

Pfizer Investigational Site

Sfax, 3013, Tunisia

Location

Pfizer Investigational Site

Tunis, 1000, Tunisia

Location

Pfizer Investigational Site

Zaghouan, 1100, Tunisia

Location

Pfizer Investigational Site

Abu Dhabi, United Arab Emirates

Location

Pfizer Investigational Site

Al Ain City, United Arab Emirates

Location

Pfizer Investigational Site

Dubai, United Arab Emirates

Location

Pfizer Investigational Site

Ras Al Khaima, United Arab Emirates

Location

Related Publications (4)

• Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.

  PMID: 30876390 DERIVED

• Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.

  PMID: 29530274 DERIVED

• Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.

  PMID: 29449941 DERIVED

• Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.

  PMID: 28983166 DERIVED

Related Links

• To obtain contact information for a study center near you, click here.

Biospecimen

Retention: NONE RETAINED

Whole Blood

MeSH Terms

Conditions

Obesity; Smoking; Dyslipidemias; Diabetes Mellitus; Hypertension

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Behavior; Lipid Metabolism Disorders; Metabolic Diseases; Glucose Metabolism Disorders; Endocrine System Diseases; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 12, 2010
• First Posted: November 18, 2010
• Study Start: July 1, 2011
• Primary Completion: April 1, 2012
• Study Completion: April 1, 2012
• Last Updated: February 18, 2021

Record last verified: 2021-02

Locations

AE (4); ZA (7); KE (2); CA (6); AL (9); KU (6); SA (6); LE (4); SE (6); EG (4); GH (5); NG (5); TU (6); JO (3)